CALLIDITAS THERAPEUTICS-ADR (CALT)
US13124Q1067 - ADR
CALLIDITAS THERAPEUTICS-ADR
NASDAQ:CALT (4/23/2024, 12:59:02 PM)
17.88
-0.2 (-1.12%)
Company Profile
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm and currently employs 174 full-time employees. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Company Info
CALLIDITAS THERAPEUTICS-ADR
D5, Kungsbron 1,
Stockholm STOCKHOLM 11122
P: 4684113005.0
CEO: Renee Aguiar-Lucander
Employees: 174
Website: https://www.calliditas.se/
CALT News
5 days ago - Calliditas TherapeuticsCalliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year...
7 days ago - Market News VideoOversold Conditions For Calliditas Therapeutics (CALT)14 days ago - Calliditas TherapeuticsCalliditas Therapeutics to Attend Conferences in April/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases...
15 days ago - Calliditas TherapeuticsCalliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced upcoming data presentations, as well as a...
15 days ago - Calliditas TherapeuticsCalliditas receives notice of allowance for United States patent application covering setanaxib in cancer treatment/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced that the Company has received a Notice of...
a month ago - Everest MedicinesEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®/PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...
CALT Twits
Here you can normally see the latest stock twits on CALT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
